news flash·2025-06-17 00:23Core Viewpoint - The recent State Council meeting has focused on optimizing drug and medical consumables procurement policies, with expectations for a marginal easing in the rules for the 11th batch of national procurement [1] Group 1: Policy Implications - The policies are expected to encourage and support the development and use of innovative drugs and medical devices, which will likely benefit and accelerate the growth of the innovative drug and device industry, enhancing its global influence [1] - Strengthened quality supervision across the entire supply chain for drugs and consumables is anticipated to favor high-quality generic and innovative leading companies, potentially leading to a more concentrated market share [1] Group 2: Investment Strategy - The investment strategy for the second half of 2025 suggests that the optimization of procurement will restore market sentiment, and the era of true innovation and internationalization in pharmaceuticals will bring returns [1] - The layout of self-controlled industrial chains under the backdrop of tariffs is expected to see multiple catalysts in the second half of the year, driving steady growth in the sector [1] - It is recommended to focus on three areas for investment in the second half of the year: innovation-driven initiatives, internationalization, and reforms in out-of-hospital marketing models, particularly in the innovative drug sector, which is seen as having the highest beta effect [1]